Shares of Biocon Ltd surged 2% to touch a day’s high of Rs 393.55 on 7th January, after the company said its subsidiary is set to introduce three new oncology biosimilars at an upcoming healthcare conference in the United States. 

The move marks a strategic expansion of its oncology portfolio. It aims to strengthen Biocon’s presence in the global biosimilars market. This will address the growing demand for accessible cancer therapies.

The new oncology biosimilars will add to Biocon’s existing pipeline, underscoring its continued focus on biologic innovation.

The announcement reflects Biocon’s push to offer affordable, high-quality cancer treatments while expanding its global presence.

The launch is also expected to showcase the company’s research progress and development milestones. Additionally, it highlights regulatory advances in oncology biosimilars. Market participants view it as a key step in strengthening Biocon’s global standing.

At 11:42 AM, shares of Biocon were trading 1.36% higher at Rs 390.40 on NSE.

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!